A study of galectin-1 as a possible therapeutic agent for amyotrophic lateral sclerosis

Galectin-1 作为肌萎缩侧索硬化症可能治疗剂的研究

• 批准号: 13670629
• 负责人: KATO Takeo
• 金额: $ 1.98万
• 依托单位: Yamagata University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2001
• 资助国家: 日本
• 起止时间: 2001 至 2002
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-13670629/
• 关键词: amyotrophic lateral sclerosis; galectin-1; motor neuron disease; oxidized galectin-1; reduced galectin-1

Background and purposeAbnormal accumulation of neurofilaments in motor neurons is a characteristic pathological finding in amyotrophic lateral sclerosis (ALS). Recently we revealed that oxidized galectin-1, which has axonal regeneration-enhancing activity, accumulates in the neurofilamentous lesions in ALS. The objective of this study was to investigate whether oxidized galectin-1 has a beneficial effect on ALS.MethodsOxidized recombinant human galectin-1 (rhGAL-1/ox) or physiological saline was injected into the left gastrocnemius muscle of transgenic mice with a mutant SOD1 (H46R), an animal model of ALS.ResultsAdministration of rhGAL-1/ox to the mice delayed the onset of motor dysfunction and prolonged the life of the mice and the duration of their illness. Motor neurons of the lumbar cord were more preserved in the mice injected with rhGAL-1/ox than in those injected with physiological saline.ConclusionThe study suggests that rhGal-1/ox administration could be a new therapeutic strategy for ALS.

背景和目的运动神经元中神经丝的异常积累是肌萎缩侧索硬化症（ALS）的特征性病理表现。最近我们发现，具有轴突再生增强活性的氧化半乳糖凝集素-1 在 ALS 的神经丝病变中积聚。本研究的目的是探讨氧化半乳糖凝集素-1是否对ALS有有益作用。方法将氧化重组人半乳糖凝集素-1（rhGAL-1/ox）或生理盐水注射到突变SOD1转基因小鼠的左侧腓肠肌中(H46R)，ALS 动物模型。结果给小鼠注射 rhGAL-1/ox 延缓了运动功能障碍的发生，并延长了寿命小鼠及其患病持续时间。与注射生理盐水的小鼠相比，注射rhGAL-1/ox的小鼠腰脊髓运动神经元得到更多保存。结论该研究表明rhGal-1/ox给药可能成为ALS的新治疗策略。

项目成果

Tobisawa S: "Mutant SOD1 linked to familial amyotrophic lateral sclerosis, but not wild-type SOD1, induces ER stress in COS7 cells and transgenic mice."Biochem Biophys Res Commun. 303. 496-503 (2003)

Tobisawa S：“与家族性肌萎缩侧索硬化症相关的突变型 SOD1（而非野生型 SOD1）会在 COS7 细胞和转基因小鼠中诱导 ER 应激。”Biochem Biophys Res Commun。

Wada M, (他4名), Kato T: "Decreased galectin-1 immunoreactivity of the skin in amyotrophic lateral sclerosis"J. Neurul. Sci.. (in press).

Wada M，（其他 4 名），Kato T：“肌萎缩侧索硬化症中皮肤半乳糖凝集素 1 免疫反应性降低”J. Neurul。

Kato, T., 他: "Galectin-1 is a component of …"Biochem.Biophys.Res.Commun.. 282. 166-172 (2001)

Kato, T., 等人：“Galectin-1 是……的一个组成部分”Biochem.Biophys.Res.Commun.. 282. 166-172 (2001)

Kikuchi K: "An N-terminal fragment of proSAAS (a granin-like neuroendcrine peptide precursor) is associated with tau inclusions in Pick's disease."Biochem Biophys Res Commun. 308. 646-654 (2003)

Kikuchi K：“proSAAS（一种粒蛋白样神经内分泌肽前体）的 N 末端片段与皮克氏病中的 tau 蛋白内含物有关。”Biochem Biophys Res Commun。

Kato T: "Galectin-1 is a component of neurofilamentous lesions in sporadic and familial amyotrophic lateral sclerosis."Biochem Biophys Res Commun. 282. 166-172 (2001)

Kato T：“Galectin-1 是散发性和家族性肌萎缩侧索硬化症中神经丝病变的一个组成部分。”Biochem Biophys Res Commun。